Natera, Inc.
NTRANasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 10/30234% above fair value
$378.92−35.38 (-8.54%)
Close on Nov 2, 2026Market cap $54.62BP/E –Yield –
Natera Tests Reported in Natera's CLIA Laboratories by Quarter
Tests Reported in Natera's CLIA Laboratories (tests)
Natera Tests Reported in Natera's CLIA Laboratories: 972,000.00 tests in Q2 2026, up 21.5% from a year earlier. That is the highest of the 20 quarters on record here.
Latest, Q2 2026
972,000.00
Period ended Jun 30, 2026
Change on a year earlier
+21.5%
799,900.00 in Q2 2025
History
20 quarters
Since Q2 2019
Sources
14
Documents cited below
Where the Q2 2026 figure comes from
“During the three months ended June 30, 2026, total reported units were approximately 985,500, comprised of approximately 972,000 tests reported in our laboratories. Comparatively, during the three months ended June 30, 2025, total reported units were approximately 812,900, which is comprised of approximately 799,900 tests reported in our laboratory.”
Source: Form 10-Q (2026-06-30) ↗
Reported in Form 10-K/10-Q MD&A (2019–2026Q2).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Tests Reported in Natera's CLIA Laboratories (tests) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 972,000.00 | +21.5% | Form 10-Q (2026-06-30) ↗ |
| Q1 2026 | Mar 31, 2026 | 918,100.00 | +16.0% | Form 10-Q (2026-03-31) ↗ |
| Q4 2025 | Dec 31, 2025 | 878,000.00 | +15.8% | Form 8-K Ex 99.1 (2026-02-26) ↗ |
| Q3 2025 | Sep 30, 2025 | 819,900.00 | +11.4% | Form 10-Q (2025-09-30) ↗ |
| Q2 2025 | Jun 30, 2025 | 799,900.00 | +12.7% | Form 10-Q (2026-06-30) ↗ |
| Q1 2025 | Mar 31, 2025 | 791,400.00 | +19.3% | Form 10-Q (2026-03-31) ↗ |
| Q4 2024 | Dec 31, 2024 | 758,200.00 | +25.5% | Form 8-K Ex 99.1 (2026-02-26) ↗ |
| Q3 2024 | Sep 30, 2024 | 735,900.00 | +28.0% | Form 10-Q (2025-09-30) ↗ |
| Q2 2024 | Jun 30, 2024 | 709,800.00 | +22.8% | Form 10-Q (2025-06-30) ↗ |
| Q1 2024 | Mar 31, 2024 | 663,500.00 | +17.2% | Form 8-K Ex 99.1 (2025-05-08) ↗ |
| Q4 2023 | Dec 31, 2023 | 604,200.00 | +19.8% | Form 8-K Ex 99.1 (2025-02-27) ↗ |
| Q3 2023 | Sep 30, 2023 | 575,000.00 | – | Form 10-Q (2024-09-30) ↗ |
| Q2 2023 | Jun 30, 2023 | 578,200.00 | – | Form 8-K Ex 99.1 (2024-08-08) ↗ |
| Q1 2023 | Mar 31, 2023 | 566,000.00 | – | Form 8-K Ex 99.1 (2024-05-09) ↗ |
| Q4 2022 | Dec 31, 2022 | 504,500.00 | +27.0% | Form 8-K Ex 99.1 (2024-02-28) ↗ |
| Q4 2021 | Dec 31, 2021 | 397,100.00 | – | Form 8-K Ex 99.1 (2023-02-28) ↗ |
| Q3 2020 | Sep 30, 2020 | 226,700.00 | +27.4% | Form 10-Q (2020-09-30) ↗ |
| Q2 2020 | Jun 30, 2020 | 208,400.00 | +19.2% | Form 10-Q (2020-06-30) ↗ |
| Q3 2019 | Sep 30, 2019 | 178,000.00 | – | Form 10-Q (2020-09-30) ↗ |
| Q2 2019 | Jun 30, 2019 | 174,800.00 | – | Form 10-Q (2020-06-30) ↗ |
Cite this data
StockData. (2026). Natera Tests Reported in Natera's CLIA Laboratories, quarterly Q2 2019–Q2 2026 [Data set]. Compiled from Natera SEC filings and investor materials. https://stockdatahq.com/stocks/ntra/kpis/vol-tests-reported-lab
See every metric in the Natera KPI table. Data updated Nov 2, 2026.